Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 4Stomach Neoplasms 2Lung Neoplasms 2Sarcoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 6Paclitaxel 3Docetaxel 3Cyclophosphamide 3eribulin 2Oncolytic Virotherapy 2tislelizumab 1tirbanibulin 1spartalizumab 1poly ICLC 1pertuzumab 1pemigatinib 1pegfilgrastim 1obinutuzumab 1ixabepilone 1fludarabine phosphate 1fludarabine 1etirinotecan pegol 1efineptakin alfa 1durvalumab 1atezolizumab 1aldesleukin 1advexin 1Yoga 1Vinorelbine 1Tomography, X-Ray Computed 1Surveys and Questionnaires 1Ritonavir 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × pemigatinib × Breast × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡